Oxidative inhibition of DNase1L3 drives age‑associated long cfDNA fragments that fuel inflamm‑aging via TLR9

Hypothesis

Age‑associated elevation of long cfDNA fragments (>175 bp) results from oxidative inhibition of the DNase1L3 nuclease, which impairs complete chromatin digestion during apoptosis and necrosis. The resulting persistently methylated DNA fragments act as endogenous TLR9 ligands, sustaining low‑grade inflammation and contributing to inflamm‑aging. Concurrently, age‑related hypermethylation of histone H1 variants loosens nucleosome packing, making chromatin more susceptible to incomplete cleavage and biasing the fragment pool toward larger sizes.

Mechanistic Basis

• Oxidative modification: Reactive oxygen species increase with age and can oxidize the catalytic histidine of DNase1L3, reducing its activity 1.
• Chromatin accessibility: Hypermethylation of histone H1 genes (e.g., H1F0, H1FX) decreases linker histone binding, producing more open chromatin that resists full nuclease digestion 1.
• Fragment signaling: Long cfDNA retains nucleosomal methylation patterns at CpG islands of inflammatory genes; when internalized by plasmacytoid dendritic cells, these fragments trigger TLR9‑dependent NF‑κB signaling, elevating MCP‑1 and IL‑6 1.

Predictions

1. Older individuals will show higher plasma levels of oxidized DNase1L3 (detected by carbonyl‑specific immunoblot) correlating positively with the proportion of cfDNA fragments >175 bp and negatively with overall DNase1L3 enzymatic activity in immunoprecipitated plasma.
2. In vitro incubation of young plasma with H2O2 will recapitulate the age‑shift in fragment size distribution, an effect reversible by adding a DNase1L3‑specific activator or a reducing agent.
3. Knock‑down of DNase1L3 in murine neutrophils will increase long cfDNA fragments and elevate serum MCP‑1, whereas overexpression will shorten fragments and reduce inflammatory markers.
4. Bisulfite sequencing of long cfDNA fractions will reveal enrichment of methylation at nucleosome‑related promoters (e.g., MORF4L1) and histone H1 loci, linking fragmentation to the methylation clock.

Experimental Design

• Human cohort: Recruit 150 participants stratified by age (20‑30, 40‑50, 60‑70, 80+ years). Collect plasma, measure cfDNA concentration, fragment size via capillary electrophoresis, DNase1L3 activity assay, oxidative modifications (oxy‑blot), and inflammation panel (MCP‑1, IL‑6, TNF‑α). Perform multivariate regression to test the predicted relationships.
• In vitro assay: Spike young plasma with increasing H2O2 concentrations (0‑500 µM), incubate 2 h at 37 °C, then assess fragment shift and DNase1L3 activity.
• Mouse model: Use LysM‑Cre to drive neutrophil‑specific shRNA against Dnase1l3 or a transgenic overexpression line. Serially bleed mice at 3, 12, and 24 months, analyze cfDNA fragment distribution and serum cytokines.

Potential Outcomes

If the hypothesis holds, oxidative inhibition of DNase1L3 will emerge as a mechanistic bridge between the methylation clock and fragment‑size alterations, offering a druggable node (e.g., DNase1L3 activators or antioxidants) to modulate inflamm‑aging. Failure to observe the predicted correlations would falsify the model and suggest that other nucleases or clearance mechanisms dominate age‑related cfDNA remodeling.